Systemic Scleroderma clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
San Francisco, California and other locations